Apellis Pharmaceuticals officer sells $564k in company stock
APLS
+1.17%
Add to/Remove from Watchlist
Add to Watchlist
Add Position
Position added successfully to:
Please name your holdings portfolio
Type:
BUY
SELL
Date:
Amount:
Price
Point Value:
Leverage:
1:1
1:10
1:25
1:50
1:100
1:200
1:400
1:500
1:1000
Commission:
Create New Watchlist
Create
Create a new holdings portfolio
Add
Create
+ Add another position
Close
WALTHAM, MA – Mark Jeffrey DeLong, Chief Business & Strategy Officer of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), has sold 9,913 shares of company stock at a price of $56.90 per share, according to a recent SEC filing. The transaction, dated March 18, 2024, resulted in a total sale amount of approximately $564,049.
The sale has adjusted DeLong’s direct ownership in the pharmaceutical company to 54,693 shares following the transaction. The filing was signed by attorney-in-fact David Watson on behalf of Mark DeLong on March 19, 2024.
Apellis Pharmaceuticals, based in Waltham, Massachusetts, is known for its focus on developing pharmaceutical preparations. The company’s shares are traded on the NASDAQ exchange under the ticker symbol APLS.
Investors often monitor insider transactions as they can provide insights into the company’s financial health and future prospects. The sale by a high-ranking executive like DeLong may attract attention from the investment community as they assess the implications for their investment strategies.
InvestingPro Insights
As investors digest the news of Mark Jeffrey DeLong’s recent stock sale of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), it’s crucial to consider the broader financial context provided by InvestingPro’s real-time data and analytics. The company’s market capitalization stands at $6.86 billion, reflecting its significant presence in the pharmaceutical industry. Despite a remarkable revenue growth of 425.83% in the last twelve months as of Q4 2023, Apellis Pharmaceuticals grapples with profitability challenges, as evidenced by a negative P/E ratio of -12.87 and an adjusted operating income margin of -130.39%.
Two InvestingPro Tips that could be particularly relevant for investors include the anticipation of sales growth in the current year and the company’s liquid assets surpassing its short-term obligations. These insights suggest potential for future financial stability, despite the current lack of profitability and weak gross profit margins. Moreover, with the stock having performed poorly over the last month, showing an 18.2% decline, investors might be looking for signs of a turnaround or reassurance in the company’s fundamentals.
For those seeking deeper analysis, InvestingPro offers additional tips regarding Apellis Pharmaceuticals, including assessments of debt levels, profitability over the past year, and return on investment metrics. To access these insights and enhance your investment strategy, consider using coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at https://www.investing.com/pro/APLS. There are 10 more InvestingPro Tips available that could provide valuable context for Apellis Pharmaceuticals’ financial outlook and stock performance.
